On the whole, the FDA’s plan, says Robert Cerwinski, JD, is “net good news for the biosimilar developers,” and should provide “tailwinds” for the industry by giving greater clarity, streamlining processes, and reducing the time and expense that biosimilar developers will need to bring their products to the marketplace.
When the FDA Commissioner Scott Gottlieb, MD, last week unveiled the FDA’s Biosimilar Action Plan, many of the document’s features centered around actions already taken by the FDA or reiterating promises to release expected deliverables. However, according to Robert Cerwinski, JD, a partner at Goodwin who focuses on litigation involving pharmaceuticals and biologics, some novel elements of the plan are cause for strong interest.
First, Cerwinski told The Center for Biosimilars® in an interview, is the fact that the FDA is working on guidance that will provide clarity on “label carveouts,” or approval for fewer than all of the indications for which a reference product is approved. In cases in which some of the indications of a reference product are covered by a patent while others are not, current guidance is unclear as to how a biosimilar product sponsor can seek approval for a portion of the drug label in a manner similar to the way in which a generic product sponsor might.
“The machinery for doing that and the law that permits that is fairly well developed in the generic world,” explained Cerwinski, and given that providing the option for label carveouts has proven to be a useful way to reduce barriers to market entry, “It’s very interesting that Commissioner Gottlieb and his staff have picked up on that and are trying to give biosimilar applicants some more clarity,” he said.
If a biosimilar were approved for an indication not covered by a patent, the biosimilar could potentially launch in that indication sooner than it would if it gained approval in all indications of the reference product. That is a possibility that could raise concerns among innovator product sponsors about a biosimilar being prescribed for off-label indications. However, “it’s unclear the extent to which a biosimilar would be prescribed for off-label uses,” said Cerwinski.
What is clear is that for biosimilar product developers, anticipated label carveouts should help companies determine their overall litigation strategies; planning well in advance which indications should be challenged through the inter partes review process will be key and could potentially streamline the Biologics Price Competition and Innovation Act litigation process.
The second feature of the plan that Cerwinski found notable is that the FDA appears to be “a little bit more activist” in terms of working with other agencies, such as the Federal Trade Commission (FTC), to remove barriers to biosimilar market entry that are not within the FDA’s purview—including cracking down on rebates provided by drug manufacturers. “In the past, FDA has not always wanted to weigh in to such disputes,” he said.
Finally, a feature of the plan that notes that the FDA is exploring the possibility of allowing the use of non—US-licensed comparator products in clinical programs that support a biosimilar application could have an impact upon yet another newly announced action of the FDA: considering the importation of drugs in cases of supply issues.
“I see no reason why, in a case of a true supply constraint, it would matter whether it was a biosimilar or a small molecule drug” that would be considered for importation, said Cerwinski. However, if a biosimilar considered for importation was approved with respect to a foreign-licensed reference product, “What sort of bridges into the US approval process can the biosimilar applicant take advantage of to make sure that the clinical trials they spend their money on abroad give them some benefit in the approval process the [United States]?” The potential for approval of biosimilars using foreign-licensed comparators could bring some clarity to that question, and to the question of which drugs could potentially be imported for US use.
On the whole, the FDA’s plan, says Cerwinski, is “net good news for the biosimilar developers,” and should provide “tailwinds” for the industry by giving greater clarity, streamlining processes, and reducing the time and expense that biosimilar developers will need to bring their products to the marketplace.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.